RxDoctor Payments Data

Thong Do, MD

Nephrology · Hanford, CANPI 1437369303

Payments from drug & device makers

$504in general payments, 2019–2025

Across 20 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$182
  • Ardelyx, Inc.$75
  • Akebia Therapeutics Inc$55
  • Baxter Healthcare$47
  • GSK$39
  • Novo Nordisk$36
  • plus $69 from 3 others

What the payments were for

  • Food & beverage$45390%
  • Education$5110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$504 in reported general payments places this provider in the 35th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$798,073
Medicare patients
559
Services billed
6,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide74$367,335
FarxigaDapagliflozin Propanediol206$166,155
LokelmaSodium Zirconium Cyclosilicate131$123,665
ProsolParenteral Amino Acid 20% No.1600$96,404
Sevelamer Hcl24$90,341
XphozahTenapanor Hcl24$61,404
VeltassaPatiromer Calcium Sorbitex50$49,754
EliquisApixaban31$31,764
Sevelamer Carbonate154$23,425
RenvelaSevelamer Carbonate11$23,180
ClinolipidFat Emulsion/Olive/Soy/Phospho50$19,595
Calcium Acetate168$19,562
Cinacalcet Hcl64$19,508
JardianceEmpagliflozin17$14,587
DapagliflozinDapagliflozin Propanediol20$11,159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$27$367,33574 claims
AstraZenecaFarxiga, Lokelma$182$289,821337 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,341 nephrology providers in California.

Other nephrology in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →